HomeCompareLJUIF vs SBUX

LJUIF vs SBUX: Dividend Comparison 2026

LJUIF yields 4.97% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $55.1K in total portfolio value· pulled ahead in Year 8
10 years
LJUIF
LJUIF
● Live price
4.97%
Share price
$0.40
Annual div
$0.02
5Y div CAGR
31.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.4K
Annual income
$28,919.95
Full LJUIF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — LJUIF vs SBUX

📍 SBUX pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLJUIFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LJUIF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LJUIF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LJUIF
Annual income on $10K today (after 15% tax)
$422.31/yr
After 10yr DRIP, annual income (after tax)
$24,581.96/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $31,382.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LJUIF + SBUX for your $10,000?

LJUIF: 50%SBUX: 50%
100% SBUX50/50100% LJUIF
Portfolio after 10yr
$130.0K
Annual income
$47,380.03/yr
Blended yield
36.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

LJUIF
No analyst data
Altman Z
2.6
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LJUIF buys
0
SBUX buys
0
No recent congressional trades found for LJUIF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLJUIFSBUX
Forward yield4.97%2.75%
Annual dividend / share$0.02$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR31.6%48.3%
Portfolio after 10y$102.4K$157.5K
Annual income after 10y$28,919.95$65,840.13
Total dividends collected$73.4K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: LJUIF vs SBUX ($10,000, DRIP)

YearLJUIF PortfolioLJUIF Income/yrSBUX PortfolioSBUX Income/yrGap
1$11,354$653.83$11,107$407.21+$247.00LJUIF
2$13,062$913.02$12,512$626.87+$550.00LJUIF
3$15,268$1,291.84$14,366$978.69+$902.00LJUIF
4$18,194$1,857.20$16,929$1,557.50+$1.3KLJUIF
5$22,189$2,721.92$20,658$2,543.80+$1.5KLJUIF
6$27,825$4,082.89$26,406$4,302.22+$1.4KLJUIF
7$36,070$6,297.08$35,877$7,622.00+$193.00LJUIF
8← crossover$48,635$10,039.66$52,741$14,352.64$4.1KSBUX
9$68,688$16,649.06$85,676$29,243.03$17.0KSBUX
10$102,416$28,919.95$157,513$65,840.13$55.1KSBUX

LJUIF vs SBUX: Complete Analysis 2026

LJUIFStock

SSY Group Limited, an investment holding company, researches, develops, manufactures, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food, beverages, and catering business. It sells its products under Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was incorporated in 2004 and is headquartered in Wanchai, Hong Kong. SSY Group Limited is a subsidiary of China Pharmaceutical Co., Ltd.

Full LJUIF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this LJUIF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LJUIF vs SCHDLJUIF vs JEPILJUIF vs OLJUIF vs KOLJUIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.